Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 86 articles:
HTML format
Text format



Single Articles


    October 2018
  1. OSTI D, Del Bene M, Rappa G, Santos M, et al
    Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.
    Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-18-1941.
    PubMed     Text format     Abstract available


  2. PASSARO C, Alayo Q, DeLaura I, McNulty JJ, et al
    Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2311.
    PubMed     Text format     Abstract available


  3. BERBERICH A, Kessler T, Thome CM, Pusch S, et al
    Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-1580.
    PubMed     Text format     Abstract available


    September 2018
  4. UNRUH D, Mirkov S, Wray B, Drumm M, et al
    Methylation-dependent Tissue Factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas.
    Clin Cancer Res. 2018 Sep 28. pii: 1078-0432.CCR-18-1222.
    PubMed     Text format     Abstract available


  5. CRUICKSHANKS N, Zhang Y, Hine S, Gibert M, et al
    Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0926.
    PubMed     Text format     Abstract available


  6. WAHL DR, Lawrence TS
    No sugar added: A new strategy to inhibit glioblastoma receptor tyrosine kinases.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-2113.
    PubMed     Text format     Abstract available


    August 2018
  7. DAVARE MA, Henderson JJ, Agarwal A, Wagner JP, et al
    Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma.
    Clin Cancer Res. 2018 Aug 31. pii: 1078-0432.CCR-18-1052.
    PubMed     Text format     Abstract available


  8. BLAKELEY JO, Grossman SA, Chi AS, Mikkelsen T, et al
    Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-0110.
    PubMed     Text format     Abstract available


    July 2018
  9. MEEL MH, de Gooijer MC, Guillen Navarro M, Waranecki P, et al
    MELK inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0924.
    PubMed     Text format     Abstract available


  10. ZINN PO, Singh SK, Kotrotsou A, Hassan I, et al
    A co-clinical radiogenomic validation study - Conserved magnetic resonance radiomic appearance of Periostin expressing Glioblastoma in patients and xenograft models.
    Clin Cancer Res. 2018 Jul 27. pii: 1078-0432.CCR-17-3420.
    PubMed     Text format     Abstract available


  11. ISHIDA CT, Zhang Y, Bianchetti E, Shu C, et al
    Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-1040.
    PubMed     Text format     Abstract available


  12. ZHANG L, Sorensen M, Kristensen BW, Reifenberger G, et al
    The oncometabolite D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas that inhibits both complement and T cells.
    Clin Cancer Res. 2018 Jul 13. pii: 1078-0432.CCR-17-3855.
    PubMed     Text format     Abstract available


  13. BARO M, Lopez Sambrooks C, Quijano A, Saltzman WM, et al
    Oligosaccharyltransferase inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
    Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0792.
    PubMed     Text format     Abstract available


    June 2018
  14. LEE EQ, Duda DG, Muzikansky A, Gerstner E, et al
    Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-18-1025.
    PubMed     Text format     Abstract available


  15. JURATLI TA, Stasik S, Zolal A, Schuster C, et al
    TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas - a pilot prospective study.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-3717.
    PubMed     Text format     Abstract available


  16. BUERKI RA, Chheda ZS, Okada H
    Immunotherapy of Primary Brain Tumors: Facts and Hopes.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-17-2769.
    PubMed     Text format     Abstract available


    May 2018
  17. VOGELBAUM MA
    Targeted Therapies for Brain Tumors: Will They Ever Deliver?
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-0855.
    PubMed     Text format     Abstract available


  18. SANAI N, Li J, Boerner J, Stark K, et al
    Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-17-3348.
    PubMed     Text format     Abstract available


  19. LU CF, Hsu FT, Hsieh KL, Kao YJ, et al
    Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.
    Clin Cancer Res. 2018 May 22. pii: 1078-0432.CCR-17-3445.
    PubMed     Text format     Abstract available


  20. ZHANG Y, Ishida CT, Ishida W, Lo SL, et al
    Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and elicits Synthetic Lethality in Glioblastoma.
    Clin Cancer Res. 2018 May 15. pii: 1078-0432.CCR-18-0260.
    PubMed     Text format     Abstract available


    April 2018
  21. WILDES TJ, Grippin A, Dyson KA, Wummer BM, et al
    Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-3061.
    PubMed     Text format     Abstract available


  22. GEDEON PC, Schaller TH, Chitneni SK, Choi BD, et al
    A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.
    Clin Cancer Res. 2018 Apr 27. pii: 1078-0432.CCR-17-0126.
    PubMed     Text format     Abstract available


  23. KESARWANI P, Prabhu A, Kant S, Kumar P, et al
    Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0041.
    PubMed     Text format     Abstract available


  24. JACKSON CM, Lim M
    Immunotherapy for glioblastoma: playing chess, not checkers.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0491.
    PubMed     Text format     Abstract available


  25. MARTINEZ-RICARTE F, Mayor R, Martinez-Saez E, Rubio-Perez C, et al
    Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3800.
    PubMed     Text format     Abstract available


    March 2018
  26. SAHA D, Wakimoto H, Peters CW, Antoszczyk SJ, et al
    Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1717.
    PubMed     Text format     Abstract available


  27. WORONIECKA KI, Rhodin KE, Chongsathidkiet P, Keith KA, et al
    T-Cell Dysfunction in Glioblastoma: Applying a New Framework.
    Clin Cancer Res. 2018 Mar 28. pii: 1078-0432.CCR-18-0047.
    PubMed     Text format     Abstract available


  28. DETTLING S, Stamova S, Warta R, Schnolzer M, et al
    Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-1839.
    PubMed     Text format     Abstract available


  29. NAKASHIMA H, Nguyen T, Kasai K, Passaro C, et al
    Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma.
    Clin Cancer Res. 2018 Mar 6. pii: 1078-0432.CCR-17-2954.
    PubMed     Text format     Abstract available


  30. LADOMERSKY E, Zhai L, Lenzen A, Lauing KL, et al
    IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3573.
    PubMed     Text format     Abstract available


    February 2018
  31. NISHIYAMA A, Yamada T, Kita K, Wang R, et al
    Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-1623.
    PubMed     Text format     Abstract available


  32. LI XN, Kogiso M, Qi L, Braun FK, et al
    Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-2256.
    PubMed     Text format     Abstract available


  33. MOHME M, Schliffke S, Maire CL, Runger A, et al
    Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-2617.
    PubMed     Text format     Abstract available


  34. HOLLON TC, Orringer DA
    Shedding light on IDH1 mutation in gliomas.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-18-0011.
    PubMed     Text format     Abstract available


  35. WORONIECKA K, Chongsathidkiet P, Rhodin KE, Kemeny HR, et al
    T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-1846.
    PubMed     Text format     Abstract available


  36. GORDON RE, Zhang L, Peri S, Kuo YM, et al
    Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2923.
    PubMed     Text format     Abstract available


  37. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Text format     Abstract available


    January 2018
  38. GOMEZ S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, et al
    A novel method for rapid molecular subgrouping of medulloblastoma.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-2243.
    PubMed     Text format     Abstract available


  39. NIMMERVOLL B, Boulos N, Bianski BM, Dapper J, et al
    Establishing A Preclinical Multidisciplinary Board for Brain Tumors.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2168.
    PubMed     Text format     Abstract available


    December 2017
  40. PAL J, Patil V, Kumar A, Kaur K, et al
    Loss-of-function mutations in Calcitonin receptor (CALCR) identify highly aggressive glioblastoma with poor outcome.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1901.
    PubMed     Text format     Abstract available


  41. UCKERMANN O, Juratli TA, Galli R, Conde M, et al
    Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
    Clin Cancer Res. 2017 Dec 19. pii: 1078-0432.CCR-17-1795.
    PubMed     Text format     Abstract available


  42. SU YT, Chen R, Wang H, Song H, et al
    Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Clin Cancer Res. 2017 Dec 18. pii: 1078-0432.CCR-17-2032.
    PubMed     Text format     Abstract available


  43. JIN X, Jin X, Kim LJY, Dixit D, et al
    Inhibition of ID1-BMPR2 intrinsic signaling sensitizes glioma stem cells to differentiation therapy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1529.
    PubMed     Text format     Abstract available


    November 2017
  44. CHANG K, Bai HX, Zhou H, Su C, et al
    Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2236.2017.
    PubMed     Text format     Abstract available


  45. WEISS T, Schneider H, Silginer M, Steinle A, et al
    NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma.
    Clin Cancer Res. 2017 Nov 21. pii: clincanres.1766.2017.
    PubMed     Text format     Abstract available


  46. MIGLIORINI D, Dietrich PY, Stupp R, Linette GP, et al
    CAR-T cell Therapies in Glioblastoma: a first look.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.2871.2017.
    PubMed     Text format     Abstract available


  47. NANDHU MS, Behera P, Bhaskaran V, Longo SL, et al
    Development of a function-blocking antibody against fibulin-3 as targeted reagent for glioblastoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1628.2017.
    PubMed     Text format     Abstract available


  48. CHEN Q, Cai J, Wang Q, Wang Y, et al
    Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0605.2017.
    PubMed     Text format     Abstract available


  49. WICK W, Kessler T
    Drug repositioning meets precision in glioblastoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.2989.2017.
    PubMed     Text format     Abstract available


    October 2017
  50. BYRON SA, Tran NL, Halperin RF, Phillips JJ, et al
    Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.
    Clin Cancer Res. 2017 Oct 26. pii: clincanres.0963.2017.
    PubMed     Text format     Abstract available


  51. ACERBI F, Broggi M, Schebesch KM, Hohne J, et al
    Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLIO).
    Clin Cancer Res. 2017 Oct 10. pii: clincanres.1184.2017.
    PubMed     Text format     Abstract available


    September 2017
  52. AVRIL T, Etcheverry A, Pineau R, Obacz J, et al
    CD90 expression controls migration and predicts dasatinib response in glioblastoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1549.2017.
    PubMed     Text format     Abstract available


  53. LI J, Wu J, Bao X, Honea N, et al
    Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients using an IVIVE-PBPK Modeling Approach.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.0983.2017.
    PubMed     Text format     Abstract available


  54. MULLER-GREVEN GM, Carlin C, Burgett ME, Ahluwalia MS, et al
    Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0249.2017.
    PubMed     Text format     Abstract available


  55. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-beta in glioblastomas.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0077.2017.
    PubMed     Text format     Abstract available


    August 2017
  56. FELSBERG J, Hentschel B, Kaulich K, Gramatzki D, et al
    Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0890.2017.
    PubMed     Text format     Abstract available


  57. ALEXANDER BM, Ba S, Berger MS, Berry DA, et al
    Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0764.2017.
    PubMed     Text format     Abstract available


  58. OLMEZ I, Brenneman B, Xiao A, Serbulea V, et al
    Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0803.2017.
    PubMed     Text format     Abstract available


  59. WANG G, Shen J, Sun J, Jiang Z, et al
    Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/beta-catenin Signaling.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0774.2017.
    PubMed     Text format     Abstract available


    July 2017
  60. ZHANG CB, Cheng W, Ren X, Wang Z, et al
    Tumor Purity As an Underlying Key Factor in Glioma.
    Clin Cancer Res. 2017 Jul 28. pii: clincanres.2598.2016.
    PubMed     Text format     Abstract available


  61. ZHAI L, Ladomersky E, Lauing KL, Wu M, et al
    Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017.
    PubMed     Text format     Abstract available


  62. PATEL SH, Poisson LM, Brat DJ, Zhou Y, et al
    T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0560.2017.
    PubMed     Text format     Abstract available


  63. OIZEL K, Chauvin C, Oliver L, Gratas C, et al
    Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.3102.2016.
    PubMed     Text format     Abstract available


  64. FAN QW, Nicolaides TP, Weiss WA
    Inhibiting 4EBP1 in glioblastoma.
    Clin Cancer Res. 2017 Jul 10. pii: clincanres.0042.2017.
    PubMed     Text format     Abstract available


  65. CANELLA A, Welker AM, Yoo JY, Xu J, et al
    Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3151.2016.
    PubMed     Text format     Abstract available


    June 2017
  66. ELLINGSON BM, Gerstner E, Smits M, Huang RY, et al
    Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials.
    Clin Cancer Res. 2017 Jun 27. pii: clincanres.2844.2016.
    PubMed     Text format     Abstract available


  67. COOK SANGAR ML, Genovesi LA, Nakamoto MW, Davis MJ, et al
    Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.2943.2016.
    PubMed     Text format     Abstract available


    May 2017
  68. GEOERGER B, Bourdeaut F, DuBois SG, Fischer M, et al
    A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Clin Cancer Res. 2017;23:2433-2441.
    PubMed     Text format     Abstract available


  69. SLANEY CY, von Scheidt B, Davenport AJ, Beavis PA, et al
    Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Clin Cancer Res. 2017;23:2478-2490.
    PubMed     Text format     Abstract available


    April 2017
  70. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Text format     Abstract available



  71. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.
    PubMed     Text format    


  72. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Text format     Abstract available


  73. BI WL, Horowitz P, Greenwald NF, Abedalthagafi M, et al
    Landscape of Genomic Alterations in Pituitary Adenomas.
    Clin Cancer Res. 2017;23:1841-1851.
    PubMed     Text format     Abstract available


    March 2017
  74. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Text format     Abstract available



  75. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  76. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Text format     Abstract available


    January 2017
  77. RING EK, Markert JM, Gillespie GY, Friedman GK, et al
    Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
    Clin Cancer Res. 2017;23:342-350.
    PubMed     Text format     Abstract available


    December 2016
  78. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Text format     Abstract available


  79. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Text format     Abstract available


    November 2016
  80. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Text format     Abstract available


  81. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


    October 2016
  82. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Text format     Abstract available


  83. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  84. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Text format     Abstract available


    September 2016
  85. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Text format     Abstract available


  86. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: